Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643043 · ClinicalTrials.gov registry record · NA
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
A NA study of Bladder Cancer and Urothelial Carcinoma, sponsored by Matthew Milowsky, MD.
- Completed
- Registry status
- NA
- Development phase
- 219
- Enrollment target
- 8
- Study locations
NCT02643043: Completed NA study of Bladder Cancer and Urothelial Carcinoma, sponsored by Matthew Milowsky, MD.
NCT02643043 is a NA study of Bladder Cancer and Urothelial Carcinoma that has completed, run by Matthew Milowsky, MD. The registered enrollment target is 219 participants, below the 12,752-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02643043, a NA study of Bladder Cancer and Urothelial Carcinoma, has completed, sponsored by Matthew Milowsky, MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 219 participants
- Enrollment target
- 8
- Study locations
Study Summary
This comprehensive genomic analysis and biospecimen repository study incorporates Next Generation Sequencing (NGS) of archival tumor tissue from 200 subjects with metastatic urothelial cancer in support of several parallel goals. The immediate goal involves generation of a comprehensive report identifying subject specific genetic mutations and/or alterations based on NGS. Additionally, DNA and RNA extracted from tumor specimens and any remaining blocks/slides from the NGS will be stored for future research. Long-term, the goal of this endeavor is to support collaborative translational research projects in metastatic urothelial cancer by allowing investigators to interrogate abstracted coded clinical data linked to data from any biospecimen studies.
Primary Outcome
Subject-specific report that includes a summary of genomic alterations and potential therapeutic options based on the specific alterations and evidence discovered.
Conditions Studied
Interventions
- OTHER Biospecimen Collection
Study Locations (8)
New York
- Ichan School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
California
- University of Southern Cailfornia - Los Angeles
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
North Carolina
- University of North Carolina - Lineberger Comprehensive Cancer Center - Chapel Hill
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Washington
- University of Washignton/Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2017-07-26 |
| Est. Completion | 2023-09-13 |
| Phase | NA |
What the finished NCT02643043 record still lists
NCT02643043 is an interventional study that assigns participants to a tested intervention. The registered 219 participants enrollment target is mid-sized for trials with a published cap, below the 12,752-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT02643043 lists 8 locations in 7 states (New York, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT02643043 about?
NCT02643043 is a clinical study titled "UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch". This comprehensive genomic analysis and biospecimen repository study incorporates Next Generation Sequencing (NGS) of archival tumor tissue from 200 subjects with metastatic urothelial cancer in support of several parallel goals. The immediate goal involves generation of a comprehensive report ident...
What is the current status of trial NCT02643043?
This trial is currently completed. It is a NA study. The enrollment target is 219 participants. The study started on 2017-07-26. Estimated completion is 2023-09-13.
What conditions does trial NCT02643043 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma, Urethral Cancer, Cancer of the Ureter.
What interventions are being tested in trial NCT02643043?
The interventions under investigation include: Biospecimen Collection (OTHER).
Who is sponsoring clinical trial NCT02643043?
This trial is sponsored by Matthew Milowsky, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02643043 being conducted?
This trial has 8 study locations across California, Illinois, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02643043's enrollment target sits among peer trials
219 54th of 175 higher than 122 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05196035 · 219 participants · Phase 3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- NCT05608434 · 219 participants · Phase 1
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
- NCT05773144 · 219 participants · NA
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
- NCT05907980 · 219 participants · Phase 1
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI